Biotech Startups

Farmless uses fermentation with microbes and renewable energy to produce proteins without relying on agricultural land. It operates in the food technology and alternative protein space.

4 investors

Kyntra Bio (formerly FibroGen) is a clinical-stage biopharmaceutical company developing therapies for oncology and rare diseases, including serious and life-threatening conditions. Its pipeline includes drug candidates such as roxadustat and FG-3246.

4 investors

1STBIO (퍼스트바이오) is a biotechnology company developing drug programs, including the HPK1 inhibitor immuno-oncology candidate FB849 and the NLY02 program. It focuses on advancing therapeutic pipelines to bring treatments to patients.

4 investors

Five Prime Therapeutics was a clinical-stage biotech in South San Francisco developing protein- and antibody-based immuno-oncology therapies, including the FGFR2b-targeting antibody bemarituzumab for gastric cancer.

4 investors

Flightpath Biosciences develops microbiome-sparing, pathogen-specific drug candidates to treat infection-associated diseases by selectively targeting harmful bacteria while preserving healthy microbial communities. The company focuses on small molecule therapeutics for chronic and complex diseases, particularly those linked to pathogenic bacteria such as Crohn's disease.

4 investors

Fluent Bio develops software for analyzing single-cell RNA sequencing data, producing count matrices and diagnostic outputs for researchers using Illumina sequencing libraries. The software is designed for genomics and life science researchers working with single-cell gene expression data.

4 investors

Foray Bioscience uses single plant cells and AI-powered software (Pando) to direct how plant matter forms, producing plant materials, molecules, and seeds without growing whole plants. Its platform serves plant innovators across packaging, textiles, therapeutics, agriculture, and ecosystem restoration by making lab-grown plant cells predictable and scalable.

4 investors

4 investors

Forever Labs collects and cryogenically stores adult stem cells for individuals and develops therapies based on stem cell rejuvenation. The company operates in the longevity and anti-aging biotech space.

4 investors

Gilead discovers, develops, and delivers therapeutic medicines for life-threatening diseases, with focus on virology, oncology, and inflammation across 35+ countries. The company combines scientific research with global partnerships to expand patient access to treatments.

4 investors

Freya Biosciences develops innovative therapies targeting immune-mediated diseases that affect women. The company is led by a team with extensive experience in bringing therapeutic drugs to market from major pharmaceutical companies.

4 investors

Frontier Health builds Juno, an AI teammate that automates repetitive, high-volume administrative work for healthcare administration teams across existing systems such as EPR, PAS, and e-RS. It is used in NHS environments to handle booking, validation, tracking, and patient-pathway communication while keeping staff in control of review and escalation.

4 investors

Gate Bioscience develops small molecule therapeutics called Molecular Gates for disease treatment. The company operates in the drug discovery and development space.

4 investors

Genemod offers a lab management platform that combines electronic lab notebook (ELN), LIMS, inventory, and equipment tracking in one data model, with AI agents that plan experiments, execute protocols across connected systems, and generate audit-ready records. It serves scientific research teams ranging from discovery labs to regulated manufacturing, including protein therapeutics, cell line development, strain design, and academic labs.

4 investors

Geneoscopy develops innovative diagnostic technologies for gastrointestinal health, specifically focused on the detection of colorectal cancer. The company serves healthcare providers and patients seeking advanced diagnostic solutions in the medical diagnostics and cancer detection sector.

4 investors

Genespire is a life sciences company backed by multiple venture capital investors including Sofinnova Partners, XGEN Venture, CDP Venture Capital, and Indaco Venture Partners. Based on the investor page content, the company operates in the biotech and life sciences sector.

4 investors

Genomics builds a genotype-phenotype database and genetic risk-prediction tools used to support pharmaceutical drug discovery and clinical trials, as well as population health management and clinical decision support for healthcare providers. It serves life sciences companies and healthcare systems through its Life Sciences and Health & Wellness divisions.

4 investors

GentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases. The company builds autologous and allogeneic Treg platforms as an alternative to systemic immune-suppressive therapies.

4 investors

Gerostate Alpha develops therapeutics aimed at aging and chronic disease. The company operates in the biotech and therapeutics space.

4 investors

Gila Therapeutics is a clinical-stage biotech company developing a topical lingual signaling platform that delivers micro-dose PYY dissolving on the tongue to activate brain regions regulating food intake and metabolism. Its treatments target obesity, type 2 diabetes, and associated cardiometabolic disorders.

4 investors

Giraffe Bio develops custom biomolecules that recover metals from low-grade ores and mining waste, serving mining companies with a drop-in technology that improves recovery rates while reducing water, energy, and chemical consumption. The company currently focuses on copper and lithium extraction with plans to expand into gold, nickel, rare earth elements, and other critical minerals.

4 investors

GondolaBio is a clinical-stage biopharmaceutical company developing therapeutics for patients with genetic diseases, with a lead oral small-molecule program (PORT-77) targeting erythropoietic protoporphyria and X-linked protoporphyria. A sister company of BridgeBio Pharma launched in 2024, it runs a decentralized drug-development model with a pipeline spanning multiple rare genetic conditions.

4 investors

GraphTx is an AI-driven platform for drug discovery that validates immunology and inflammation drug targets using live patient samples before clinical trials. The company serves pharmaceutical researchers by applying machine learning to patient immune cell data to reduce development risk and failure rates.

4 investors

4 investors